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ABSTRACT OF THE DISSERTATION 
 
Effects of Cigarette Smoking on Neurocognitive Performance in 
Dementia Patients 
 
by 
Christina Mannino 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, September 2014 
Dr. Holly Morrell, Chairperson 
 
Dementia has become a serious problem worldwide due to the rapidly increasing 
incidence rate and the lack of effective treatments that cure or slow disease progression, 
and thus. prevention is crucial. Some studies suggests that cigarette smoking may 
increase the risk of developing dementia, but others suggest that smoking may have a 
neuroprotective effect. To clarify our understanding of the relationship between cigarette 
smoking and dementia, this study examined the effects of smoking on multiple cognitive 
domains via secondary data analysis of a sample consisting of 54% female subjects with 
an average age of 58±13 years. Measures of executive function, verbal memory, 
attention, and processing speed were administered to two groups of dementia patients, 
never smokers and current/former smokers. Hierarchical linear regression analysis was 
used to test smoking status as a predictor of functioning in each of these four cognitive 
domains after controlling for potentially confounding factors such as cardiovascular 
disease, type 2 diabetes, depression, anxiety, and substance use. No relationship was 
found between smoking, any of the covariates, and cognitive performance in any domain. 
Future research should utilize a prospective design and administer neuropsychological 
 ix 
batteries to participants in early or middle adulthood who have not been yet diagnosed 
with dementia. 
 
 1 
CHAPTER ONE 
INTRODUCTION 
 
Dementia has become a serious worldwide problem, as it is the leading cause of 
functional limitation among older adults (APA, 2012). In developed countries, the 
prevalence of dementia ranges from 5% to 10% in individuals over age 65 and affects as 
many as 50% of the population age 85 and older (Rincon & Wright, 2013). In the United 
States alone, one in three adults will develop dementia or suffer a stroke in their lifetime. 
Even more startling is the fact that the prevalence of Alzheimer’s disease (AD), an illness 
characterized by plaques and tangles in the brain, early onset memory impairment, 
deficits in naming and visuoconstruction abilities, and social withdrawal (Schoenberg & 
Duff, 2011), doubles every 4.3 years. Additionally, AD is currently the sixth leading 
cause of death in the U.S. and the fifth leading cause in people over age 65. (Alzheimer’s 
Association, 2012). Perhaps the most disheartening fact concerning dementia is that 
among the top 10 leading causes of death in the U.S., AD is the only one without a cure, 
a course of prevention, or even a way to slow its progression (Alzheimer’s Association, 
2012). Moreover, the current Alzheimer’s disease literature posits that the complex 
pathophysiological process of AD begins years, and perhaps even a decade or more, 
before the symptoms manifest; therefore, prevention is crucial (Sperling, Karlawish, & 
Johnson, 2013).  
Similarly, the prevalence of vascular dementia (VaD), a disease typified by early 
deficits in attention, executive function, processing speed, and visuoconstruction skills 
(Schoenberg & Duff, 2011), doubles every 5.3 years (Rincon & Wright, 2013). 
Unfortunately, there is a lack of literature on the rate of increase in prevalence of 
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dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD). Estimates of the 
prevalence of DLB, an illness notable for abnormal protein aggregates known as Lewy 
Bodies, motor impairment, fluctuating mental clarity, and vivid visual hallucinations of 
people or animals (Schoenberg & Duff, 2011), are as high as 5% in the general 
population and 30.5% of all dementia cases, rendering DLB the second most common 
type of dementia after AD (Zaccia, McCracken, & Brayne, 2005). Epidemiological data 
also suggest that FTD, a disease characterized by early onset of executive dysfunction 
and personality changes and impairments in confrontation naming and verbal fluency 
(Schoenberg & Duff, 2011), has an incidence and prevalence similar to AD as a common 
cause of early onset dementia in individuals younger than 65 years of age (Rabinovici & 
Miller, 2010). These statistics, in conjunction with the prediction that by the year 2030 
the portion of the U.S. population over age 65 will double, suggest that health care costs 
associated with dementia will increase substantially (Hurd et al., 2013). Given that there 
are no cures for dementia in the foreseeable future, prevention is the key, but it is not 
possible unless the risk factors of dementia are identified. 
A number of factors thought to increase the risk of dementia have been described 
in the literature. The risk factors most commonly discussed are age, family history, 
hypertension, high cholesterol, diabetes, depression, cigarette smoking, and alcohol use 
(Mayo Clinic Staff, 2014). While age and family history cannot be changed, the other 
factors can be avoided, prevented, or controlled by lifestyle changes, such as 
improvements in diet and exercise, quitting smoking, and/or adhering to treatment with 
medication. In particular, cigarettes are probably the most significant source of chemical 
toxins in humans. They are the leading preventable cause of death in the United States 
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(U.S. Department of Health and Human Services, 2014) and have been forecasted by the 
World Health Organization as being the cause of death for approximately nine million 
people per year globally by the year 2030 (Swan & Lessov-Schlaggar, 2007). Smoking is 
associated with an increased incidence of cardiovascular disease including 
cerebrovascular disease, coronary heart disease, and vascular diseases.  
Given the association between smoking and cardiovascular disease, and the link 
between cardiovascular disease and increased risk for dementia (Peters, 2012), it is not 
surprising that a number of studies have suggested a link between cigarette smoking and 
AD and VaD (Peters et al., 2008; Rincon & Wright, 2013; Rusanen et al., 2011; Swan & 
Lessov-Schlaggar, 2007). In contrast, a study examining the potential relationship 
between cigarette smoking and the risk of neuropathologic changes of Lewy-related 
pathology (LRP) in the brain (Tsuang et al., 2009) found that smoking was associated 
with significantly reduced relative risk for LRP, which is characteristic of DLB and 
sometimes found in cases of AD. However, this is only one study, and more 
investigations into the relationship between smoking and DLB are necessary to determine 
if tobacco reduces the risk of DLB. In the case of frontotemporal dementia, very little is 
known about the risk factors associated with this dementia as compared with AD and 
VaD (Kalkonde et al., 2012). Therefore, we need a better understanding of cigarette 
smoking as a potential risk factor for the various types of dementia. 
Cardiovascular damage is not the only way in which smoking may be connected 
to the development of a neurodegenerative disorder. Many of the more than 4,700 
constituents of cigarette smoke are associated with brain toxicity, such as hydrogen 
cyanide, arsenic, and vinyl chloride, a chemical thought to be connected with brain 
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cancer (Fowles & Dybing, 2003). Especially problematic are the heavy metals present in 
tobacco smoke, such as lead and cadmium, which in recent epidemiological studies have 
been shown to be a risk factor for AD pathology (i.e., plaques and tangles) via an 
increase in oxidative stress (Bernhard, Rossmann, & Wick, 2005; Liu et al., 2006). 
Lifetime exposure to lead is cross-sectionally associated with cognitive decline in 
executive functioning, verbal memory and learning, visual learning, processing speed, 
language, and visual construction, as well as decreases in brain volume and increases in 
the number of white matter lesions (Shih et al., 2006). Cigarettes are also a significant 
source of oxidative stress through direct exposure, the inflammatory immune response 
pathway, and glutamate neurotoxicity (Swan & Lessov-Schlaggar, 2007). Oxidative 
stress refers to cell injury mediated by reactive oxygen and nitrogen species. Oxidative 
stress is currently thought to play an important part in the neurodegenerative process of 
AD as the resulting damage has been reported extensively in AD patients (Practicò, 2008, 
Wang et al., 2013). The reactive species, unavoidable byproducts of normal metabolic 
reactions, are generally chemically unstable and highly reactive. When an excess of these 
reactive species are present in a biological system they are capable of oxidizing DNA, 
RNA, protein, and lipids, resulting in cell damage (Wang et al., 2013).  
Given all of the known toxic effects of cigarette smoke on the human body, the 
relationship between smoking and cognitive decline/dementia would seem to be 
intuitively obvious, but that is not the case. The literature in this area is mixed, with some 
studies suggesting an increased risk for dementia and others suggesting that tobacco 
actually protects against dementia. For example, a number of prospective studies have 
found a significant association between increased risk of dementia and current cigarette 
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smoking (Hirayama et al., 1992; Juan et al., 2004; Launer et al., 1999; Merchant et al., 
1999; Ott et al., 1998; Reitz et al., 2005). Additional prospective studies have also 
demonstrated a significant link between smoking and increased risk of cognitive decline 
that does not meet the DSM-IV criteria for dementia (Aggarwal et al., 2006; Collins et 
al., 2009; Galanis et al., 1997; Nooyens et al., 2008; Ott et al., 2004; Reitz et al., 2005; 
Sabia et al., 2008). Finally, another prospective study conducted on women participants 
found that avoiding cigarette smoking significantly predicted maintenance of cognitive 
function (Barnes et al., 2007).  
While the majority of prospective studies have demonstrated a positive 
association between smoking and dementia, a prospective study conducted in Taiwan 
showed that cigarette smoking decreased the risk of cognitive decline (Wang et al., 
2010). The results of this study may be due to participant attrition, which was attributed 
to death or loss to follow-up. The literature suggests that smoking-related mortality may 
mask the association between Alzheimer’s disease and smoking (Chang, Zhao, Lee, & 
Ganguli, 2012; Kryscio et al., 2013). Two additional prospective studies have suggested 
that there is no link between smoking and dementia. A prospective analysis from the 
Canadian Study of Health and Aging found that smoking was not related to the risk of 
AD (Lindsay et al., 2002). Another prospective study of wine and tobacco consumption 
suggested that smoking is associated with a decreased risk of decline in attention and 
visuospatial functioning (Leibovici et al., 1999).   
In contrast, a number of case-control studies conducted in the 1980s and early 
1990s showed that smoking might protect individuals from the onset of AD. Lee (1994) 
performed a meta-analysis on 13 of these case-control studies and found that there was a 
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40% reduction in risk of AD among cigarette smokers. Several articles have posited that 
the seemingly counterintuitive results may be due to biases in study design (Kukull, 
2001; Anstey et al., 2007; Cataldo, Prochaska, & Glantz, 2010). Case-control studies can 
be biased if the way in which cases and controls are identified and enrolled is associated 
with smoking history. These types of studies can also be biased if smoking history is 
obtained differently for cases and controls. Recall bias is also a well-known problem of 
case-control studies. For the smoking case-control studies, recall bias results from 
discrepancies in the reporting of smoking status by case and control participants (Kukull, 
2001). Unsurprisingly, a meta-analysis of the case-control studies conducted by Lee 
(1994), who was a paid statistical consultant for the tobacco industry (Cataldo, 
Prochaska, & Glantz, 2010), observed the same trend as the original case-control studies. 
Regardless of Lee’s admonition that “prospective studies are often more scientifically 
valid than case-control studies,” the tobacco industry continued to fund case-control 
studies. It should also be noted that a meta-analysis performed by Cataldo, Prochaska, 
and Glantz (2010) found that even after controlling for study design, tobacco industry 
affiliation was associated with findings of decreased risk of AD in smokers. Given the 
conflicting current literature and the urgent need to ascertain dementia risk factors, it is 
important to determine the nature of the relationship between smoking and dementia as 
well as the cognitive domains that are affected by cigarette smoking. 
Studies examining the level of risk of cognitive impairment or decline among 
former smokers compared to never smokers have also produced equivocal results. One 
reason for these mixed results is that few of the studies investigating the relationship 
between smoking and risk of dementia or cognitive decline differentiated between long-
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term ex-smokers and recent ex-smokers (Sabia et al., 2012). A number of studies have 
found that ex-smokers either have similar declines in cognition or slower declines than 
never smokers due to the ambiguous definition of former smokers (Anstey et al., 2007; 
Peters et al., 2008; Sabia et al., 2012). The studies that differentiated between the two 
levels of ex-smokers found that long-term former smokers exhibited similar risk of 
cognitive impairment as never smokers (Galanis et al., 1997; Sabia et al., 2012). Almeida 
et al. (2011) found that the cognitive scores of chronic smokers (i.e., smoked a minimum 
of five cigarettes per day for a continuous period of 12 months or more throughout their 
lifetime) who quit smoking for a minimum of 18 months were comparable to those of 
never smokers. In contrast, it is possible that long-term former smokers’ risk may be 
reduced to the level of never smokers’ risk, although more research is needed to clarify 
this. The tobacco literature indicates that many of the body’s systems damaged by 
cigarette smoking return to the condition of a nonsmoker when the smoker has abstained 
from smoking for a long enough duration (e.g., risk of coronary heart disease is the same 
as for nonsmokers after 15 years of abstinence; Abrams et al., 2003). Given that the heart 
and lungs heal, and a number of the studies of the relationship between smoking and 
cognition found no differences between the cognition of never smokers and long-term ex-
smokers (Galanis et al., 1997; Sabia et al., 2012), it is possible that the brain heals as well 
or that a reduction in cardiovascular risk translates into a reduction in the risk for 
dementia. 
The variability in the procedures utilized for testing cognition is another potential 
source of inconsistent outcomes in studies on the link between smoking and dementia. A 
number of studies (Juan et al., 2004; Ott et al., 2004; Wang et al., 2010) measured 
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cognitive decline using only the Mini-Mental State Examination (MMSE; Folstein, 
Folstein, & McHugh, 1975) or the Short Portable Mental Status Questionnaire (SPMSQ; 
Pfeiffer, 1975). The MMSE and SPMSQ both have good specificity, but limited 
sensitivity (Lezak, 2004). The MMSE is most effective at distinguishing participants with 
moderate to severe cognitive deficits from control participants, but less effective at 
distinguishing control participants from those with mild deficits. Unlike many 
neuropsychological tests, these screening measures use a cutoff score rather than 
comparing each participant’s score with the scores of other individuals the same age. In 
the case of the MMSE, a cut-off score of 24 is applied without accounting for potential 
differences due to the participant’s age or level of education, which are factors known to 
affect measures of cognition. Furthermore, using a cut-off of 24 may lead to incorrectly 
classifying a participant with subtle or focal cognitive deficits. The lack of sensitivity of 
these measures and the use of cutoff scores is problematic when studying the possible 
relationship between smoking and dementia because of the risk of type II errors. 
Screening measures such as the MMSE are more likely to fail to detect dementia, 
especially early in the disease process, than a measure with good sensitivity that is 
normed by age and education level.  
As with most brief screening instruments, the MMSE and SPMSQ are affected by 
age (Lezak, 2004). For example, in a sample of community-dwelling participants, the 
average number of correct items on the SPMSQ dropped from 7.8 among participants 
ages 65 to 69 to 6.05 among participants ages 85 to 89 (Scherr et al., 1988). Given that 
cognition declines with age even in healthy individuals, the scores for ages 70 to 97 are 
likely to be lower than those for ages 18 to 69 (Soubelet & Salthouse, 2011) on a measure 
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such as the MMSE, regardless of health and lifestyle factors. These age effects may make 
it difficult to detect differences in cognitive functioning due to smoking because a study 
with an age range of 55 to 70 is likely to produce different results compared to a study 
with an age range of 65 to 80, regardless of whether participants are current smokers. 
Another problem with studies using single, gross measures of cognitive functioning such 
as the MMSE is that cognitive impairment is a multifaceted phenomenon and cannot be 
accurately determined from the results of a single test (Lezak, 2004).  
Another limitation of existing studies on the relationship between dementia and 
smoking is that they have used computerized neuropsychological tests (Paul et al., 2006), 
which have the advantage of being administered to all participants in exactly the same 
way, as well as not requiring trained neuropsychologists for administration. However, 
given the absence of a qualified neuropsychologist and that the participants are limited to 
pushing keys to register their answers on a computer test, potential cognitive deficits are 
determined solely through quantitative methods. Subtle or focal deficits are often missed 
without the observations of trained evaluators (Lezak, 2004). In addition, within a group 
of elderly participants there are apt to be a number of participants who have little or no 
computer experience; their unfamiliarity and potential discomfort with the technology 
may affect their test scores. Therefore, the lack of significant differences between current 
smokers and never or former smokers in these studies may be due to participants in both 
groups lacking familiarity with computers or experiencing computer related anxiety 
(Lezak, 2004). Given the limitations of using brief screening instruments and 
computerized testing to measure cognitive impairment in smokers, it is important that 
future studies use more sensitive and comprehensive testing batteries. 
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The majority of studies on the relationship between smoking and dementia were 
not able to ascertain the specific cognitive functions affected by cigarette smoking due to 
their use of brief screening measures. The investigations that utilized more 
comprehensive batteries to determine participant eligibility did not describe the cognitive 
deficits associated with smoking. Therefore, a brief search of the literature on the 
relationship between smoking and cognitive function was conducted to determine which 
areas of cognitive function might be most impaired due to smoking. These studies have 
demonstrated an association between current smoking and cognitive decline in four 
cognitive domains: executive function, verbal memory, attention, and information 
processing speed (Arntzen et al., 2011; Dregan, Stewart, & Gulliford, 2012; Sabia et al., 
2009; Starr et al., 2007). For example, Dregan, Steward, and Gulliford (2012) 
investigated the relationship between cardiovascular risk factors, including smoking, 
blood pressure, cholesterol levels, and BMI, and cognitive decline in individuals age 50 
and older who participated in the English Longitudinal Study of Aging. Cognition was 
measured in terms of verbal memory, and executive function was measured in terms of 
verbal fluency. Smokers were divided into two groups: never smokers or ex-smokers and 
current smokers. The study found that cigarette smoking was the most consistent vascular 
risk predictor for cognitive decline across all outcomes. An earlier longitudinal study 
(Whitehall II Study; Sabia et al., 2009) examined the association between health 
behaviors such as smoking, alcohol consumption, physical activity, and diet, and 
cognition in late midlife. The cognitive domains evaluated were again verbal memory 
and executive function; however, this study measured abstract reasoning as well as verbal 
fluency. The results suggested that the greater the exposure to smoking across midlife, 
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the higher the odds that the verbal memory and executive function of participants was 
poor. While it is important to determine whether or not an association exists between 
smoking and cognitive function, future studies need to utilize multiple measures and 
assess the effects of smoking across all cognitive domains in order to gain a greater 
understanding of the ways in which cigarette smoke affects the human brain. 
In addition to increasing the breadth and sensitivity of measures of cognitive 
function, it is important for future studies on the relationship between cigarette smoking 
and dementia to control for potential confounding variables. There are several likely 
candidates, including cardiovascular disease, type 2 diabetes, substance use, depression, 
and anxiety. Cardiovascular disease and diabetes are well-known risk factors for vascular 
dementia, Alzheimer’s disease, and cognitive decline (Blom, Emmelot-Vonk, & Koek, 
2013; Ng, Turek, & Hakim, 2013; Luchsinger, 2012). Epidemiologic studies have also 
shown that cigarette smoking increases the incidence of myocardial infarction and 
coronary artery disease (Ambrose & Barua, 2004). Research indicates that type 2 diabetes 
is also associated with both cognitive decline and cigarette smoking. Specifically, a 
number of studies have reported an association between type 2 diabetes and dementia, 
including AD and VaD (Roberts et al., 2013). A longitudinal cohort study of 800 older 
participants found that the participants diagnosed with type 2 diabetes had a 65% higher 
risk of incidence than those who were not diagnosed with diabetes (Arvanitakis et al., 
2004). Additionally, a large number of studies have found an association between active 
cigarette smoking and increased incidence of type 2 diabetes (Willi et al., 2007).  
Depression and anxiety are also associated with both cognitive decline and 
cigarette smoking (Brady, Haynes, Hartwell, & Killeen, 2013; Holma et al., 2013). In 
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older adults, mild depression appears to be associated with subtle weaknesses in visual 
memory and nonverbal aspects of general intelligence. However, older adults with 
moderate to severe depression demonstrate mild weaknesses in information processing 
speed and executive skills (Boone et al., 1995). Depression is not the only disorder 
commonly diagnosed in older adults; anxiety is also fairly prevalent in this population 
especially individuals with mild cognitive impairment (MCI). An increasing body of 
research has shown an association between anxiety and declines in cognitive function in 
older adults. This research suggests that older adults with clinical levels of anxiety have 
poorer global cognitive function, episodic memory, and aspects of executive function 
such as set shifting as compared to non-anxious age-matched controls (Pietrzack et al., 
2012).  
According to the literature on the association between nicotine dependence and 
psychiatric disorders, approximately 50% of daily smokers have a history of a psychiatric 
disorder and they smoke a disproportionately large percentage of the overall number of 
cigarettes consumed (Grover, Goodwin, & Zvolensky, 2012). Moreover, individuals who 
successfully quit smoking have fewer lifetime depression diagnoses and depressive 
symptoms than those who are unsuccessful quitters and current smokers (Jamal, Van der 
Does, Cuijpers, & Penninx, 2012). Current smokers with a diagnosis of Major Depressive 
Disorder (MDD) have more difficulty quitting than smokers who do not meet the criteria 
for MDD and are more likely to be heavy smokers. Furthermore, the severity of 
depressive symptoms is associated with the number of days smoked and the number of 
cigarettes smoked per day. There also appears to be a bi-directional relationship between 
nicotine dependence and anxiety disorders, as the research has found that smoking may 
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result in increased anxiety, and individuals experiencing increased levels of anxiety are 
more likely to smoke (Moylan, Jacka, Pasco, & Berk, 2013). In fact, nicotine dependent 
individuals are more than twice as likely to develop an anxiety disorder than any other 
psychiatric disorder. Additionally, the National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC) found that the 12-month prevalence rates of nicotine 
dependence were elevated in individuals with panic disorder (Brady, Haynes, Hartwell, & 
Killeen, 2013).  
Chronic substance use has also been shown to be associated with cognitive 
impairment and is highly comorbid with tobacco use. While the research focused on 
determining the existence of a relationship between chronic substance abuse and an 
increased risk of dementia is not yet conclusive, there have been a number of studies that 
demonstrated cognitive impairments in chronic substance users. A recent meta-analysis 
suggested that chronic exposure to opiates results in cognitive impairment across a range 
of different neuropsychological domains, especially verbal working memory, and 
cognitive flexibility in the context of verbal fluency (Baldacchino et al., 2012). For 
chronic methamphetamine users, cognitive impairments are most likely seen in 
attention/working memory, information processing speed, learning and memory, 
executive function, and motor skills (Weber et al., 2012). Repeated ketamine users 
demonstrate impairments in spatial working memory, planning, visual recognition, and 
semantic memory (Liang et al., 2013).  
The research on the association between alcohol consumption and the risk of 
dementia or cognitive impairment is more complicated than that for the drugs mentioned 
above. As might be expected, heavy chronic alcohol consumption without comorbidities 
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and nutritional deficits appears to result in cognitive impairment, specifically involving 
memory and executive function (Sinforiani et al., 2011). In contrast, a number of studies 
suggest that light-to-moderate alcohol consumption (i.e., no more than two drinks per 
day) has a protective effect on cognition similar to the protective effect on the 
cardiovascular system (Anstey, Mack, and Cherbuin, 2009; Sinforiani et al. 2011). While 
the majority of the cardiovascular protective effects seem to be attributed to the 
flavenoids in red wine with antioxidant properties, these protective effects have been 
noted for white wine, beer, and distilled spirits as well. According to the literature, the 
degree of cognitive impairment has been associated with sex (Mancinelli, Vitali, & 
Ceccanti, 2009), duration of abuse, the amount of alcohol consumed, and possibly the age 
of abuse onset (Sinforiani et al., 2011).  
As was mentioned earlier, tobacco use is highly comorbid with the use of alcohol 
and illicit drugs. More than 75% of alcohol and drug dependent individuals early in the 
recovery process smoke cigarettes and are often characterized as heavy, highly nicotine-
dependent smokers (Kalman, Morrisette, & George, 2005). Approximately 80% of 
cocaine users and opioid dependent individuals also smoke cigarettes. The Harvard 
College Alcohol Study, a survey of over 14,000 randomly chosen college students, found 
that students were significantly more likely to smoke cigarettes if they used alcohol and 
marijuana (Tullis et al., 2003). 
Given that cigarette smoke contains over 4700 neurotoxic compounds; is 
associated with increased risk of hypertension and diabetes; and is comorbid with 
substance use, depression, and anxiety, all of which are risk factors for dementia, it is 
reasonable to hypothesize that cigarette smoking is related to cognitive decline and 
 15 
dementia. Therefore, the goal of the current study was to evaluate the effects of cigarette 
smoking on cognitive function in four key domains identified in the literature: executive 
function, verbal memory, attention, and information processing speed in participants 
diagnosed with dementia, after controlling for covariates that have been shown to be 
related to both cigarette smoking and dementia in the scientific literature (cardiovascular 
disease, type 2 diabetes, substance use, depression, and anxiety). We posited that 
cigarette smoking would negatively affect neuropsychological performance in patients 
with a dementia diagnosis. In other words, dementia patients who are current smokers 
would perform worse on neuropsychological measures of executive function, verbal 
memory, attention, and information processing speed than dementia patients who are 
long-term ex-smokers or never smokers. In terms of the covariates, the supposition was 
that the more cigarettes smoked later in life, the more cognitive impairment would be 
noted in domains affected by these factors. Specifically, smoking along with the presence 
of cardiovascular disease, depression, or anxiety would be associated with impairments in 
executive function and attention/working memory, substance abuse would result 
primarily in executive function dysfunction, and type 2 diabetes would be associated with 
attention and information processing speed impairments. 
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CHAPTER TWO 
METHOD 
 
Participants 
 Participants were patients referred to Harbor UCLA Medical Center for 
neuropsychological testing between 1991 and 2011 who were diagnosed with AD, VaD, 
mixed dementia (VaD and AD), DLB, FTD, or dementia not otherwise specified (NOS). 
The sample consisted of 45.6% males (N = 52) and 54.4% females (N = 62). The ages 
ranged from 24 to 85 (M = 58.16, SD = 12.85). The racial/ethnic composition of the 
sample was 35.2% African American, 30.6% Caucasian, 14.8% Hispanic, 13.8% Asian, 
0.9% Middle Eastern, and 4.6% other. The average level of education was 12.35 years 
(SD = 3.04), and ranged from 3 to 18 years. In terms of dementia diagnosis, the sample 
comprised 52.1% patients diagnosed with dementia NOS, 24.5% with VaD, 12.3% with 
AD, 3.7% DLB, 3.7% with FTD, 2.5% with mixed dementia, and 1.2% dementia due to 
substance abuse (Table 1). Average participant cognitive performance is shown in Table 
2. 
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Table 1 
Participant Demographics 
 M SD N(%) 
Age (years) 58.16 12.85  
Education (years) 12.35   3.04  
Gender     
   Female   62(54.4) 
   Male   52(45.6) 
Ethnicity:    
   African American   38(35.2) 
   Caucasian   33(30.6) 
   Hispanic   16(14.8) 
   Asian   15(13.9) 
   Middle Eastern     1(0.9) 
   Other     5(4.6) 
Dementia Type:    
   Dementia NOS   85(52.1) 
   Vascular Dementia   40(24.5) 
   Alzheimer’s Disease    20(12.3) 
   Lewy Body Dementia     6(3.7) 
   Frontal Temporal Dementia     6(3.7) 
   Mixed Dementia     4(2.5) 
   Dementia due to Substance 
Abuse 
    2(1.2) 
    
Chronic History:   No Yes 
   Hypertension   38(40.4) 56(59.6) 
   Diabetes   67(72.8) 25(27.2) 
   Depression   63(61.8) 39(38.2) 
   Anxiety   93(90.3)  10( 9.7) 
   Substance Use   72(72.7) 27(27.2) 
   Tobacco Use   51(62.6) 31(37.8) 
 
Table 2 
Participant Cognitive Performance 
Neuropsychological Measures N M SD 
   WAIS-III Digit Span 111 6.70 2.66 
   WAIS-III Digit Symbol Coding 80 6.84 14.83 
   DKEFS Phonemic Fluency 105 16.69 10.67 
   RAVLT 60 1.33 1.79 
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Measures 
Participants were referred for a one-day neuropsychological assessment, 
evaluating performance in all cognitive domains: general intellectual functioning, 
attention/working memory, language, visuospatial skills, verbal memory, non-verbal 
memory, executive functioning, information processing speed, and motor skills. These 
assessments typically lasted approximately eight hours. The evaluations involved a 
battery of approximately 21 primarily paper and pencil tests, though the composition of 
the battery varied somewhat over time. The current study examined participant 
performance in the four cognitive domains that research indicates are most affected by 
chronic cigarette smoking: executive function, verbal memory, attention/working 
memory, and information processing speed. In each domain, one test was selected that 
had good internal consistency reliability, had been used in other studies of smoking and 
cognitive decline, and had been administered to the majority of participants. 
 
Executive Function 
The majority of studies measure executive function using variations of verbal 
fluency tasks. Verbal fluency is a cognitive function that facilitates information retrieval 
from memory using frontal systems abilities such as selective attention and mental set 
shifting. The typical verbal fluency test comprises two tasks, a phonemic fluency task 
that involves the generation of as many words as possible that begin with a specified 
letter within one minute (e.g., FAS) and a semantic fluency task that requires the 
participant to list as many items as s/he can in a specified category (e.g., animals) within 
the same time period. For the current study, we chose the Delis-Kaplan Executive 
Function System Verbal Fluency Test (DKEFS Verbal Fluency, Delis, Kaplan, & 
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Kramer, 2001), with the letters F, A, S for the phonemic fluency subtest, and the category 
of animals for the semantic fluency subtest, because the test has good internal consistency 
and validity. The internal consistency of the phonemic fluency subtest ranges from .77 to 
.90 for ages 20 – 89. While the internal consistency for the semantic fluency subtest is 
lower than that of the phonemic fluency subtest (.61 to .76 for the same age range), the 
reliability coefficients are comparable to those published for a number of other 
commonly used neuropsychological tests, including the Wisconsin Card Sorting Test 
(Delis, Kramer, Kaplan, & Holdnack, 2004). 
 
Verbal Memory 
The measures used in the literature to evaluate verbal memory take the form of 
list learning tasks that involve a list of unrelated words that are presented verbally with 
immediate and delayed recall trials (e.g., Rey Auditory Verbal Learning [RAVLT], 
California Verbal Learning Test – second edition [CVLT-II]). The RAVLT was utilized 
in the current study due to a high internal reliability score (approximately .90; van den 
Burg & Kingma, 1999), the measure’s high sensitivity to neurological impairments and 
memory deficits in patients with a variety of disorders (Powell et al., 1991), and the fact 
that it correlates moderately well with other measures of learning and memory such as the 
Wechsler Memory Scale Logical Memory subtest (Johnstone et al., 2000). The RAVLT 
requires the examinee to learn a list of 15 words over five trials. Following the five trials, 
the examinee is presented with a distractor list and then asked to recall the list of words. 
After a 30-minute delay, the examinee is again asked to recall the list of words, and then 
 20 
presented with another list of words comprising words from the initial list and words that 
were not on the initial list and asked if s/he recognizes each word as being on the first list. 
 
Attention/Working Memory 
The current study utilized the Wechsler Adult Intelligence Scale – third edition 
(WAIS-III) Digit Span subtest as a measure of simple attention/working memory. Digit 
span is composed of two parts: Digit Span forward and Digit Span backwards. In Digit 
Span forward, the examinee is presented with an increasingly longer auditory sequence of 
digits comprising the numbers zero through nine and asked to repeat the sequence in the 
exact order in which it was presented. In contrast, in Digit Span backwards the examinee 
is presented a sequence of digits similar to those in the forward portion of the task and 
asked to verbally respond with the digit sequence in reverse order. The internal 
consistency for WAIS-III Digit Span ranges from .85 to .99, depending on the age group 
(for age ranges 30-54, 55-74, & 75-89; Iverson, 2001). 
 
Information Processing Speed 
Given that the WAIS-III Digit Symbol Coding subtest was utilized in a number of 
investigations into the relationship between smoking and changes in cognitive function 
(Arntzen et al., 2011, Starr et al., 2007), it was a logical choice for the current study. 
Patients are presented a key that contains digits one through nine and the symbol that 
corresponds to each digit. They are given rows of boxes where the top box contains a 
digit and the bottom box is empty then asked to fill the bottom boxes with the symbols 
corresponding with the digits in the top box as fast as they can. The digit-symbol coding 
 21 
score is the number of correct symbols completed in 120 seconds. As with the majority of 
neuropsychological measures, the Digit Symbol subtest assesses more than one cognitive 
domain. Tests of information processing speed such as Digit Symbol Coding require 
intact attention, and cognitive flexibility as well as processing speed to be successfully 
completed (Baudouin et al., 2009; Ziegler, 2010). Specifically, Digit Symbol Coding 
requires the participant to attend to (attention) and process the stimuli as quickly as 
possible (information processing speed), while switching back and forth between 
symbols and numbers (cognitive flexibility). According to the WAIS-III technical 
manual, the Digit Symbol Coding subtest has an average reliability of .82 (The 
Psychological Corporation, 1997). 
 
Tobacco Use 
The tobacco data were collected by asking each participant the question “do you 
have a history of tobacco use”. The tobacco item required a response of “yes” or “no”.  
 
Covariates 
Medical data were collected by asking each participant, “do you have a history of 
chronic hypertension,” and “do you have a history of diabetes.” The medical items all 
required “yes” or “no” answers. In addition, participants were asked, “do you have a 
history of chronic depression,” “do you have a history of chronic anxiety,” “do you have 
a history of chronic alcohol use,” “do you have a history of chronic cocaine use,” “do you 
have a history of chronic amphetamine use,” and “list any other chronic substances 
used.” The definition of “chronic” for the current study was substance use of more than 
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one year. The psychiatric/substance use items all required “yes” or “no” answers. For the 
present study, participants’ responses on all substance use questions were combined into 
one substance use variable, indicating whether they had a chronic history of any type of 
substance use (yes or no). 
 
Procedures 
Patients were primarily referred for testing by the Psychiatry, Neurology, and 
Neurosurgery departments at Harbor-UCLA Medical Center. Additionally, patient 
referrals were received from other hospitals and mental health clinics in the surrounding 
community. Patients were referred for neuropsychological evaluation in order to 
characterize their current cognitive abilities in the context of complaints of memory 
decline. The assessment process began with a brief explanation of neuropsychological 
assessment and the purpose of the evaluation. Patient confidentiality was discussed and 
informed consent was obtained for each participant. A clinical interview, which lasted 
approximately one hour, was conducted. Each patient was administered a thorough test 
battery that utilized multiple tests to evaluate each cognitive domain (i.e., general 
intellectual function, attention/information processing speed, language, visuospatial 
ability, verbal and nonverbal memory, and executive function), as well as mood and 
motor ability. The tests were all paper and pencil tests administered by a trained clinical 
neuropsychologist. 
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CHAPTER THREE 
RESULTS 
 
Four separate hierarchical multiple linear regression analyses were conducted to 
determine if tobacco use is associated with poorer performance on neuropsychological 
measures of executive function, attention, information processing speed, and verbal 
memory after controlling for cardiovascular disease, diabetes, depression, anxiety, and 
substance use. Prior to analysis, the data were evaluated for outliers and multicollinearity, 
as well as to determine if the data violated the assumptions of homoscedasticity, 
independence of residuals, and normality of residuals. The data violated the normality 
assumption. One outlier was removed from the data for each of the four cognitive 
measures and an additional outlier was removed from the WAIS-III Digit Span data. 
Based on the evaluation of normal probability plots, a logarithmic transformation was 
used to normalize the data because they still violated the normality assumption after the 
removal of outliers.  
To increase statistical power, we simplified the full regression models predicting 
WAIS-III Digit Span, WAIS-III Digit Symbol Coding, and the DKEFS phonemic fluency 
by only including the independent variables with effect sizes (sr2) greater than .01. The 
regression model predicting scores on the RAVLT (Table 8) was not simplified or 
interpreted, as the data for the modified model violated the normality assumption for all 
of the mathematical transformations attempted. A square root transformation was used 
instead of the logarithmic transformation to normalize the data for the simplified models, 
based on evaluations of normal probability plots. . The results of independent t-tests 
conducted indicated no significant differences in cognitive performance between 
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participants with and without a history of hypertension, diabetes, depression, anxiety, 
substance use, or tobacco use, with one exception (Table 3). Individuals with diabetes 
performed significantly better on WAIS-III  Digit Span than individuals without diabetes, 
t(89) = -2.26, p < .05. Correlations among the variables used in the regression models 
demonstrated positive relationships between hypertension and diabetes, hypertension and 
depression, diabetes and attention/working memory performance, executive function 
performance and attention/working memory performance, as well as tobacco use and 
other substance use (Table 4). 
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Table 3 
Group Differences for Cognitive Test Performance 
DV IV Yes (SD) No (SD) t df p Cohen’s d 
Digit Span Hypertension 6.68 (2.12) 6.73 (2.89) .10 91 .92 -.021 
 Diabetes 7.56 (2.29) 6.30 (2.39) -2.26 89 .03 .539 
 Depression 6.62 (2.086) 6.37 (2.70) -.50 98 .62 .101 
 Anxiety 6.90 (2.47) 6.45 (2.50) -.54 99 .59 -.300 
 Substance Use 6.26 (2.41) 6.56 (2.55) .52 95 .60 -.121 
 Tobacco Hx 6.26 (2.18) 6.39 (2.39) .25 78 .81 -.057 
Digit Symbol        
 Hypertension 4.44 (3.45) 4.40 (2.45) -.05 66 .96 .014 
 Diabetes 4.42 (2.27) 4.57 (3.38) .18 66 .86 -.049 
 Depression 3.84 (1.73) 7.14 (14.48) 1.26 72 .21 -.301 
 Anxiety 4.50 (2.07) 5.88 (11.71) .33 73 .74 -.125 
 Substance Use 4.55 (3.94) 6.17 (12.84) .58 74 .56 -.148 
 Tobacco Hx 4.12 (2.21) 4.06 (2.70) -.08 56 .94 .024 
FAS        
 Hypertension 17.23 (10.73) 14.78 (8.79) -1.13 87 .26 .258 
 Diabetes 16.29 (10.67) 15.71 (9.73) -.24 85 .81 .059 
 Depression 16.35 (10.03) 15.67 (9.78) -.33 92 .74 .070 
 Anxiety 21.22 (9.59) 15.49 (9.74) -1.68 93 .10 .595 
 Substance Use 15.67 (8.83) 15.75 (10.43) .03 89 .97 -.008 
 Tobacco Hx 15.07 (7.71) 15.16 (10.21) .04 73 .97 -.010 
RAVLT        
 Hypertension 1.60 (2.05) 1.00 (1.41) -1.11 51 .27 .370 
 Diabetes 1.80 (1.82) 1.31 (1.87) -.87 52 .39 .269 
 Depression 1.18 (1.65) 1.50 (1.90) .65 56 .52 -.174 
 Anxiety 1.20 (2.17) 1.37 (1.78) .20 57 .84 -.096 
 Substance Use .94 (1.20) 1.52 (1.98) 1.38 48.02 .17 -.329 
 Tobacco Hx 1.21 (1.65) 1.60 (2.06) .68 42 .50 -.211 
Note. Bold values of Cohen’s d indicate effect sizes exceeding the recommended minimum effect size of .41 
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Table 4 
Intercorrelations among Covariates and Cognitive Test Performance 
Measure 1 2 3 4 5 6 7 8 9 10 
1. History of Hypertension --          
2. History of Diabetes .277 --         
3. History of Depression .237 .072 --        
4. History of Anxiety -.036 -.012 .148 --       
5. History of Tobacco Use .146 .033 -.020 .128 --      
6. History of Substance Use -.093 -.064 -.116 .055 .393 --     
7. WAIS-III Digit Span -.033 .217 .072 .047 -.046 -.064 --    
8. WAIS-III Digit Symbol Coding .007 -.022 -.147 -.039 .011 -.067 -.202 --   
9. DKEFS Phonemic Fluency .084 .008 .094 .145 .016 .025 .512 -.054 --  
10. Rey Auditory Verbal Learning .154 .120 -.086 -.027 -.104 -.148 -.174 .245 .162 -- 
Note. Bold correlation values are significant at p < .05. 
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The author hypothesized that within a sample of dementia patients those who 
were current smokers would perform worse on select neuropsychological measures of 
executive function, verbal memory, attention, and information processing speed than 
those who are nonsmokers. Hierarchical regressions predicting cognitive performance 
from tobacco use history after controlling for history of hypertension, diabetes, 
depression, anxiety, and substance use were conducted to test this prediction. Results of 
the full, originally hypothesized regression models can be found in Tables 5 – 8, and 
results of the simplified regression models can be found in Tables 9 – 11. Contrary to the 
hypothesis, smoking did not significantly affect performance on measures of executive 
function, verbal memory, attention, or information processing speed in patients diagnosed 
with dementia, p > .05. In addition, none of the covariates significantly predicted 
cognitive performance in any domain, in either the full or simplified regression models, p 
> .05. 
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Table 5 
Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Span Performance 
(Full Model, Logarithmic Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper] p sr2 
1 Hypertension -.015 .041 -.047 [-.097, .067] .723 .00194 
 Diabetes .087 .046 .245 [-.004, .179] .060 .05476 
 Depression .047 .042 .143 [-.036, .131] .260 .01932 
 Anxiety .008 .067 .014 [-.127, .134] .908 .00020 
 Substance Use -.014 .044 -.040 [-.102, .073] .746 .00160 
2 Hypertension -.024 .042 -.075 [-.108, .060] .575 .00476 
 Diabetes .087 .046 .243 [-.004, .178] .062 .05382 
 Depression .051 .042 .155 [-.033, .135] .227 .02220 
 Anxiety -.007 .069 -.013 [-.145, .131] .919 .00014 
 Substance Use -.030 .046 -.083 [-.122, .063] .523 .00608 
 Tobacco History .045 .043 .139 [-.042, .131] .307 .01588 
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Table 6 
Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Symbol Coding 
Performance (Full Model, Logarithmic Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper] p sr2 
1 Hypertension .011 .086 .021 [-.163, .185] .897 .00036 
 Diabetes -.084 .093 -.142 [-.272, .105] .376 .01742 
 Depression .003 .081 .006 [-.161, .167] .969 .00004 
 Anxiety -.007 .120 -.009 [-.248, .234] .953 .00008 
 Substance Use -.086 .086 -.148 [-.259, .088] .325 .02161 
2 Hypertension .008 .088 .014 [-.170, .185] .931 .00017 
 Diabetes -.088 .095 -.149 [-.280, .105] .363 .01877 
 Depression .009 .084 .016 [-.161, .178] .920 .00023 
 Anxiety -.016 .124 -.020 [-.266, .235] .900 .00036 
 Substance Use -.094 .091 -.163 [-.278, .090] .309 .02371 
 Tobacco History .026 .087 .049 [-.150, .201] .768 .00194 
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Table 7 
Results of a Multiple Linear Regression Analysis Predicting DKEFS Phonemic Fluency 
Performance (Full Model, Logarithmic Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper] p sr2 
1 Hypertension -.011 .133 -.011 [-.278, .256] .934 .00012 
 Diabetes .030 .149 .027 [-.268, .327] .842 .00068 
 Depression .185 .134 .183 [-.085, .454] .175 .03098 
 Anxiety .133 .232 .074 [-.332, .597] .570 .00533 
 Substance Use .071 .143 .065 [-.215, .358] .620 .00410 
2 Hypertension -.032 .135 -.033 [-.302, .238] .816 .00090 
 Diabetes .015 .149 .014 [-.284, .314] .919 .00017 
 Depression .195 .135 .194 [-.075, .466] .153 .03460 
 Anxiety .070 .241 .039 [-.413, .552] .773 .00137 
 Substance Use .011 .155 .010 [-.300, .323] .942 .00008 
 Tobacco History .145 .147 .146 [-.149, .439] .328 .01588 
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Table 8 
Results of a Multiple Linear Regression Analysis Predicting RAVLT Long Delay Performance (Full 
Model, Logarithmic Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper] p sr2 
1 Hypertension .139 .277 .091 [-.432, .701] .619 .00689 
 Diabetes .251 .303 .144 [-.365, .867] .414 .01877 
 Depression -.145 .271 -.093 [-.695, .406] .597 .00792 
 Anxiety -.178 .462 -.064 [-1.116, .761] .703 .00410 
 Substance Use -.214 .259 -.138 [-.741, .313] .414 .01877 
2 Hypertension .154 .287 .100 [-.431, .739] .597 .00810 
 Diabetes .250 .308 .143 [-.376, .876] .422 .01877 
 Depression -.150 .276 -.096 [-.710, .411] .591 .00828 
 Anxiety -.183 .469 -.066 [-1.137, .771] .699 .00436 
 Substance Use -.185 .291 -.119 [-.778, .408] .530 .01145 
 Tobacco History -.067 .283 -.045 [-.643, .510] .815 .00160 
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Table 9 
Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Span Performance 
(Simplified Model, Square Root Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper]  p sr2 
1 Diabetes 203 .113 .214 [-.021, .428] .076 .04537 
 Depression .048 .106 .053 [-.164, .259] .653 .00281 
2 Diabetes .201 .113 .211 [-.025, .427] .080 .04452 
 Depression .048 .106 .054 [-.164, .260] .652 .00292 
 Tobacco History .080 .102 .093 [-.124, .283] .437 .00865 
 
 
Table 10 
Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Symbol Coding 
Performance (Simplified Model, Square Root Transformation) 
     95% Cl   
Step Predictor Variable B SE β [Lower, Upper] p sr2 
1 Diabetes -.061 .176 -.043 [-.411, .290] .731 .00185 
 Substance Use -.044 .173 -.032 [-.389, .301] .801 .00102 
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Table 11 
Results of a Multiple Linear Regression Analysis Predicting DKEFS Phonemic Fluency Performance 
(Simplified Model, Square Root Transformation) 
     95% Cl   
Step 
Predictor 
Variable 
B SE β [Lower, Upper] p sr2 
1 Depression .306 .323 .111 [-.338, .950] .347 .01232 
2 Depression .308 .324 .112 [-.339, .954] .346 .01254 
 Tobacco History .232 .324 .084 [-.414, .878] .477 .00706 
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CHAPTER FOUR 
DISCUSSION 
 
Results of regression models predicting performance in select cognitive domains 
did not confirm the primary hypothesis that participants diagnosed with dementia who are 
current smokers would perform worse on measures of executive function, 
attention/working memory, verbal memory, and information processing speed than those 
who are current nonsmokers. Although the sample sizes for the RAVLT and WAIS-III 
Digit Symbol Coding tests were small, the null results are unlikely to be due to low 
statistical power because the effect sizes for the majority of the independent variables in 
the regression models were less than .001. This means that most of the independent 
variables account for less than .1% of the variance in the performance on the 
neuropsychological measures investigated, which would not be clinically significant even 
if it were statistically significant. Furthermore, simplifying the models to increase 
statistical power did not yield any significant results and the effect sizes were still very 
small (less than .01).  
The only potential statistical issue encountered in the current study was the odd 
finding that participants with diabetes performed significantly better on a measure of 
simple auditory attention/working memory than participants without diabetes. The 
literature does not support this finding. In fact, studies typically show that individuals 
with diabetes perform more poorly on tests of cognitive function (e.g., Mehrabian et al. 
2011). This questionable outcome may be due to Type 1 error as a result of the large 
number of t-tests (24) performed on the data. If we apply the Bonferroni correction for 
Type I error to the number of t-tests that were conducted (corrected alpha = .05/24), then 
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the cutoff for significance becomes .002, which renders the effect of diabetes on digit 
span performance no longer significant. 
Given that the null results are most likely not due to statistical problems, one 
explanation for the current findings may simply be that cigarette smoking does not affect 
cognitive functioning. However, there are enough studies that have suggested a 
relationship between cigarette smoking and cognitive decline that the null findings of the 
current study are more likely to be attributable to methodological limitations. One 
methodological limitation was our inability to separate the participants into two groups, 
long-term ex-smokers and never smokers, and current smokers and recent ex-smokers, 
because the data were archival. As such, the data did not include the information 
necessary to split smokers into these groups. A number of studies have found that ex-
smokers either have similar declines in cognition or slower declines than never smokers 
due to the ambiguous definition of former smokers (Anstey et al., 2007; Peters et al., 
2008; Sabia et al., 2012). The studies that differentiated between the two levels of ex-
smokers found that long-term former smokers exhibited similar risk of cognitive 
impairment as never smokers (Galanis et al., 1997; Sabia et al., 2012). Almeida et al. 
(2011) found that the cognitive scores of chronic smokers (i.e., smoked a minimum of 
five cigarettes per day for a continuous period of 12 months or more throughout their 
lifetime) who quit smoking for a minimum of 18 months were comparable to those of 
never smokers. In fact, it is possible that long-term former smokers’ risk may be reduced 
to the level of never smokers’ risk, although more research is needed to confirm this. 
The tobacco literature indicates that many of the body’s systems damaged by 
cigarette smoking return to the condition of a nonsmoker when the smoker has abstained 
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from smoking for a long enough duration (e.g., risk of coronary heart disease is the same 
as for nonsmokers after 15 years of abstinence; Abrams et al., 2003). Given that the heart 
and lungs heal, and a number of the studies of the relationship between smoking and 
cognition found no differences between the cognition of never smokers and long-term ex-
smokers (Galanis et al., 1997; Sabia et al., 2012), it is possible that the brain heals as well 
or that a reduction in cardiovascular risk translates into a reduction in the risk for 
dementia. Therefore, future studies should categorize ex-smokers as either recent or long-
term ex-smokers to account for the body’s ability to heal itself. Similar temporal 
arguments may also apply to several of the other independent variables. Factors that may 
cause neurological damage, such as hypertension, diabetes, or substance use, likely cause 
cognitive deficits to a degree that depends on the severity, duration, and recency of the 
insult. 
Another issue that may have affected the primary outcome of the study was that 
smoking may be more likely to be associated with certain types of dementia than others, 
but we had to combine patients with different dementia diagnoses into one large group 
because there were not enough patients diagnosed with the different types of dementia to 
examine them separately. The most common types of dementias stem from different 
changes in brain pathology such as the amyloid beta plaques and tau tangles that 
characterize AD (Hashimoto, Rockenstein, Crews, & Masliah, 2003); the abnormal 
accumulation of α-synuclein in neuronal cell bodies, axons, and synapses found in DLB 
(Hashimoto, Rockenstein, Crews, & Masliah, 2003); and the hemorrhagic, ischemic, or 
hypoperfusive lesions that are the hallmark of VaD (Roman & Benavente, 2003). 
Therefore, it is not unreasonable to posit that smoking may affect each of these disease 
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processes differently. In fact, a study by Reitz et al. (2007) found an association between 
current smoking and increased risk of AD but not of VaD, which suggests that the 
relationship between smoking and risk of a neurodegenerative disease may not be the 
same for the different types of dementias. Future work needs to be conducted to 
determine if there are differences in the association between smoking and increased risk 
of different types of dementia, as well as whether or not smoking exacerbates or changes 
the symptomatology of the different dementias. 
The results of Rusanen et al.’s investigation (2011) not only indicated that the 
relationship between current smoking and increased risk of dementia was stronger for 
VaD than AD, they also suggested that the association was dose dependent. These 
associations were only seen in participants who currently smoked more than two packs 
per day. The increased risk of VaD in participants who currently smoked one to two 
packs per day was trending toward statistical significance, while the risk of AD in 
participants who currently smoked one to two packs per day was not significant. Neither 
the increased risk of VaD or AD was significant for participants who currently smoked 
less than one pack per day. In the current study’s sample, the majority of participants who 
currently smoked reported that they smoked one pack of cigarettes or less per day (M = 
.41, SD = .54). If the outcome is dose dependent, as suggested by Rusanen et al. (2011), 
then participants in the current study may not have smoked enough cigarettes to influence 
the development of dementia or to differentially affect their cognitive performance (i.e., 
more than 2 packs per day). 
In addition, the smoking history data were collected by self-report, which is 
potentially problematic given this sample. According to the test scores for several verbal 
 38 
memory measures, the majority of the participants are likely to be amnestic, and therefore 
the accuracy of their reported cigarette consumption may be questionable. Future work 
should check the accuracy of the information collected from participants using 
biochemical verification of smoking status (to the extent possible) and brief interviews 
with non-amnestic friends or family members. 
The complex nature of the sample analyzed for the current study gave us the 
opportunity to conduct this investigation using a diverse sample that is more reflective of 
real life, rather than one that is primarily Caucasian and homogenous in terms of 
diagnosis. Unfortunately, the complexity may have also obscured any clear-cut 
relationships among the variables due to decreased internal validity. There were many 
uncontrolled factors that may have influenced cognitive performance, such as varying 
levels of SES, various cultural backgrounds, or histories of homelessness, domestic 
violence, or other trauma. For example, several studies on the effects of homelessness on 
neuropsychological functioning have found deficits in information processing speed 
(Seidman et al., 1997) and executive functioning (Gonzalez, Dieter, Natale, & Tanner). 
Another factor that may explain the null results of the current study was the use of 
a cross-sectional design. Unlike a prospective study, the participants in a cross-sectional 
study are only assessed at one point in time, and thus there is only one opportunity to 
observe an effect. Utilizing a prospective study design would have enabled us to observe 
changes in cognitive performance over time, particularly in relation to changes in 
smoking habits. Future work should recruit smokers and non-smokers in early or middle 
adulthood, and assess their smoking behavior and cognitive performance over time.  
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In the case of the current study, it is probable that participants were at different 
points in the neurodegenerative disease process, which may have affected study 
outcomes. For example, we may be more likely to see an association between smoking 
and poorer performance on select neuropsychological tests early in the disease process, 
because later on individuals’ cognition is more likely to be severely impaired across 
multiple domains. Thus, future studies should include participants who are identified as 
early as possible in the disease process. However, the only way to determine that 
participants are at an optimal point in their disease for detecting differences is if they 
undergo neuropsychological testing, which would make recruiting participants difficult.  
 Although the use of a prospective design would have been more 
methodologically robust, we would still have encountered the problem that statistical 
modeling of the effect of smoking on AD patients is complicated by the existence of 
competing risk due to mortality (Chang, Zhao, Lee, & Ganguli, 2012). Given that 
smokers tend to die at an earlier age than non-smokers, the older smokers in our sample 
are likely to be the healthiest smokers for a given age group, which suggests that we may 
be comparing cognitive performance between nonsmokers and the healthiest smokers. 
The differences in the cognitive skills between these groups may be much smaller than in 
a comparison with unhealthier smokers who are either deceased or have more urgent 
health issues to deal with than cognitive decline. Similar arguments apply to the other 
variables that could affect mortality, including hypertension, diabetes, substance use, and 
even depression. For example, individuals with severe hypertension or uncontrolled 
hypertension may not live long enough to develop dementia or experience a decline in 
cognition, and therefore samples of older participants with hypertension may comprise 
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healthier hypertensive individuals that are more likely to have milder cognitive deficits 
than individuals with more severe hypertension who survived to the same age. 
A more likely reason for the null results is that the cognition of participants at the 
time of testing was so impaired that the predicted small effect of smoking or any of the 
other independent variables on cognitive performance was obscured due to a ceiling 
effect. Examination of the scores for the measure of verbal memory (RAVLT) showed 
that the average participant was able to recall only one word and more than half of the 
participants could not recall any of the words, which suggests that the participants were 
predominantly amnestic and fairly advanced in the disease process. Further evidence of 
the level of participant memory impairment is that the average participant scored in the 
impaired range for another test of verbal memory with the same duration of delay, WMS-
III Logical Memory II. 
Possible directions for future research include better separation of subjects into 
groups based on the amount and recency of their tobacco consumption, and use of 
techniques other than self-report to confirm smoking history and status. More research 
needs to be conducted that focuses on potential associations between cigarette smoking 
and the risk of different types of dementias, given the differences in pathology and 
mechanisms of neurodegeneration. Most importantly, future investigations should use a 
prospective design to study changes in cognition over time. Utilizing a prospective design 
that begins in early or middle adulthood and involves administering repeated 
neuropsychological batteries over time may help resolve the problems caused by recall 
bias, differential mortality, and evaluation of participants at different stages in the 
neurodegenerative process.  
 41 
REFERENCES 
 
Abrams, D. A., Leslie, F., Mermelstein, R., Kobus, K., & Clayton, R. R. (2003). 
Trandisciplinary tobacco use research. Nicotine & Tobacco Research, 5(S1), S5-
S10. 
Ambrose, J. A., & Barua, R. S. (2004). The pathophysiology of cigarette smoking and 
cardiovascular disease. Journal of the American College of Cardiology, 43(10), 
1731-1737. 
Aggarwal, N., Bienias, J. L., Bennett, D. A., Wilson, R. S., Morris, M. C., Schneider, J. 
A., . . . Evans, D. A. (2006). The relation of cigarette smoking to incident 
Alzheimer’s disease in a biracial urban community population. 
Neuroepidemiology, 26, 140-146. 
Anstey, K. J., Mack, H. A., & Cherbuin, N. (2009). Alcohol consumption as a risk factor 
for dementia and cognitive decline: meta-analysis of prospective studies. 
American Journal of Geriatric Psychiatry, 17, 542-555. 
Anstey, K. J., von Sanden, C. Salim, A., & O’Kearney, R. (2007). Smoking as a risk 
factor for dementia and cognitive decline: A meta-analysis of prospective studies. 
American Journal of Epidemiology, 166(4), 367-378. 
Arntzen, K. A., Schirmer, H., Wilsgaard, T. & Mathiesen, E. B. (2011). Impact of 
cardiovascular risk factors on cognitive function: The Tromso study. European 
Journal of Neurology, 18, 737-743. 
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., & Evans, D. A. (2004). Diabetes Mellitus 
and risk of Alzheimer disease and decline in cognitive function. Archives of 
Neurology, 61, 661-666. 
Baldacchino, A., Balfour, D. J. K., Passetti, F., Humphris, G., & Matthews, K. (2012). 
Neuropsychological consequences of chronic opiod use: A quantitative review 
and meta-analysis. Neuroscience and Biobehavioral Reviews, 36, 2056-2068. 
Barnes, D. E., Cauley, J. A., Lui, L.-Y., Fink, H. A., McCulloch, C., Stone, K. L., & 
Yaffe, K. (2007). Women who maintain optimal cognitive function into old age. 
Journal of the American Geriatric Society, 55, 259-264. 
Baudouin, A., Clarys, D., Vanneste, S., & Isingrini, M. (2009). Executive functioning and 
processing speed in age-related differences in memory: Contribution of a coding 
task. Brain and Cognition, 71, 240-245. 
Bernhard, D., Rossmann, A., & Wick, G. (2005). Metals in cigarette smoke. IUBMB Life, 
57(12), 805-809. 
 42 
Blom, K., Emmelot-Vonk, M. H., & Koek, H. L. (2013). The influence of vascular risk 
factors on cognitive decline in patients with dementia: A systematic review. 
Maturitas, 76, 113-117. 
Boone, K. B., Lesser, I. M., Miller, B. L., Wohl, M., Berman, N., Lee, A., . . . Back, C. 
(1995). Cognitive functioning in older depressed outpatients: Relationship of 
presence and severity of depression to neuopsychological test scores. 
Neuropsychology, 9(3), 390-398. 
Brady, K. T., Haynes, L. F., Hartwell, K. J., & Killeen, T. K. (2013). Substance use 
disorders and anxiety: A treatment challenge for social workers. Social Work in 
Public Health, 28, 407-423.  
Cataldo, J. K., Prochaska, J. J., & Glantz, S. A. (2010). Cigarette smoking is a risk factor 
for Alzheimer’s disease: An analysis controlling for tobacco industry affiliation. 
Journal of Alzheimer’s disease, 19, 465-480. 
Chang, C.-C. H., Zhao, Y., Lee, C.-W., & Ganguli, M. (2012). Smoking, death, and 
Alzheimer disease, a case of competing risks. Alzheimer Disease and Associated 
Disorders, 26, 300-306. 
Collins, N., Sachs-Ericsson, N., Preacher, K. J., Sheffield, K. M., Markides, K. (2009). 
Smoking increases risk for cognitive decline among community-dwelling older 
Mexican Americans. American Journal of Geriatric Psychiatry, 17, 934-942. 
Delis, D. C., Kramer, J. H., Kaplan, E., & Holdnack, J. (2004). Reliability and validity of 
the Delis-Kaplan Executive Function System: An update. Journal of the 
International Neuropsychological Society, 10, 301-303. 
Dregan, A., Stewart, R., & Gulliford, M. C. (2013). Cardiovascular risk factors and 
cognitive decline in adults aged 50 and over: A population-based cohort study. 
Age and Ageing, 42(3), 338-345. 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: A practical 
method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatric Research, 12, 189-198. 
Fowles, J., & Dybing, E. (2003). Application of toxicological risk assessment principles 
to the chemical constituents of cigarette smoke. Tobacco Control, 12, 424-430. 
Galanis, D. J., Petrovitch, H. Launer, L. J., Harris, T. B., Foley, D. J., & White, L. R. 
(1997). Smoking history in middle age and subsequent cognitive performance in 
elderly Japanese-American men. American Journal of Epidemiology, 145(6), 507-
515. 
Gonzalez, E. A., Dieter, J. N. I., Natale, R. A., & Tanner, S. L. (2001). 
Neuropsychological evaluation of higher functioning homeless persons: a 
 43 
comparison of an abbreviated test battery to the Mini-Mental State Exam. The 
Journal of Nervous and Mental Disease, 189(3), 176-181. 
Grover, K. W., Goodwin, R. D., & Zvolensky, M. J. (2012). Does current versus former 
smoking play a role in the relationship between anxiety and mood disorders and 
nicotine dependence. Addictive Behaviors, 37, 682-685. 
Hirayama, T. (1992). Large cohort study on the relation between cigarette smoking and 
senile dementia without cerebrovascular lesions. Tobacco Control, 1, 176-179.  
Holma, I. A. K., Holma, M., Melartin, T. K., Ketokivi, M., & Isometsä, E. T. (2013). 
Depression and smoking: A 5-year prospective study of patients with major 
depressive disorder. Depression and Anxiety, 30, 580-588. 
Hashimoto, M., Kawahara, K., Bar-On, P., Rockenstein, E., Crews, L., & Masliah, E. 
(2004). The Role of -synuclein assembly and metabolism in the pathogenesis of 
Lewy body disease. Journal of Molecular Neuroscience, 24, 343-352. 
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013). 
Monetary cost of dementia in the United States. New England Journal of 
Medicine, 368(14), 1326-1334. 
Iverson, G. L. (2001). Interpreting change on the WAIS-III/WMS-III in clinical samples. 
Archives of Clinical Neuropsychology, 16, 183-191. 
Jamal, M. Van der Does, A. J. W. Cuijpers, & Penninx, B. W. H. H. (2012). Association 
of smoking and nicotine dependence with severity and course of symptoms in 
patients with depressive or anxiety disorder. Drug and Alcohol Dependence, 126, 
138-146. 
Johnstone, B., Vieth, A. Z., Johnson, J. C., & Shaw, J. A. (2000). Recall as a function of 
single versus multiple trials: Implications for rehabilitation. Rehabilitation 
Psychology, 45, 3-19. 
Juan, D., Zhou, D. H. D., Li, J., Wang, J. Y. J., Gao, C., & Chen, M. (2004). A 2-year 
follow-up study of cigarette smoking and risk of dementia. European Journal of 
Neurology, 11, 277-282. 
Kalkonde, Y. V., Jawaid, A., Qureshi, S. U., Shirani, P., Wheaton, M., Pinto-Patarroyo, 
G. P., & Schulz, P. E. (2012). Medical and environmental risk factors associated 
with frontotemporal dementia: A case-control study in a veteran population. 
Alzheimer’s & Dementia, 8, 204-210. 
Kalman, D., Morrisette, S. B., & George, T. P. (2005). Co-morbidity of smoking in 
patients with psychiatric and substance use disorders. American Journal of 
Addiction, 14(2) 106-123. 
 44 
Kryscio, R. J., Abner, E. L., Lin, Y., Cooper, G. E., Fardo, D. W., Jicha, G. A., . . . 
Schmitt, F. A. (2013). Adjusting for mortality when identifying risk factors for 
transitions to MCI and dementia. Journal of Alzheimer’s Disease, 35(4), 823-832. 
Kukull, W. A. (2001). The association between smoking and Alzheimer’s disease: 
Effects of study design and bias. Biological Psychiatry, 49, 194-199.  
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., . . . 
Hoffman, A. (1999). Rates and risk factors for dementia and Alzheimer's disease: 
Results from EURODEM pooled analyses. Neurology, 52(1), 78-84. 
Lee, P. N. (1994). Smoking and Alzheimer’s disease: A review of the epidemiological 
evidence. Neuroepidemiology, 13, 131-144. 
Leibovici, D., Ritchie, K., Ledesert, B., & Touchon, J. (1999). The effects of wine and 
tobacco consumption on cognitive performance in the elderly: A longitudinal 
study of relative risk. International Journal of Epidemiology, 28, 77-81. 
Lezak, M. D., Howieson, D. B., & Loring, D. W. (2004). Neuropsychological 
assessment. New York, NY: Oxford University Press. 
Liang, H. J., Lau, C. G., Tang, A., Chan, F., Ungvari, G. S., & Tang, W. K. (2013). 
Cognitive impairments in poly-drug ketamine users. Addictive Behaviors, 38, 
2661-2666. 
Lindsay, J. Laurin, D., Verreault, R., Herbert, R., Hellwell, B., Hill G. B., & McDowell, 
I. (2002). Risk factors for Alzheimer’s disease: A prospective analysis from the 
Canadian Study of Health and Aging. American Journal of Epidemiology, 150(5), 
445-453. 
Liu, G. J., Huang, W. D., Moir, R. D., Vandenburg, C. R., Lai, B., Peng, Z. C., . . . 
Huang, X. D. (2006). Metal exposure and Alzheimer’s pathogenesis. Journal of 
Structural Biology, 155(1), 45-51. 
Luchsinger, J. A. (2012). Type 2 diabetes and cognitive impairment: Linking 
mechanisms. Journal of Alzheimers Disease, 30(0), S185-S198. 
Mancinelli, R., Vitali, M. & Ceccanti, M. (2009). Women, alcohol, and the environment: 
An update and perspectives in neuroscience. Functional Neurology, 24(2), 77-81. 
Mayo Clinic Staff. (2014, May 6). Dementia Risk Factors. Retrieved from 
http://www.mayoclinic.org/diseases-conditions/dementia/basics/risk-factors/con-
20034399 
Mehrabian, S., Raycheva, M., Gateva, A., Todorova, G., Angelova, P., Traykova, M., . . . 
Traykov, L. (2012). Cognitive dysfunction profile and arterial stiffness in type 2 
diabetes. Journal of the Neurological Sciences, 322(1-2), 152-156. 
 45 
Merchant, C., Tang, M.-X., Albert, S., Manly, J., Stern, Y., & Mayeux, R. (1999). The 
influence of smoking on the risk of Alzheimer's disease. Neurology, 52(7), 1408-
1412. 
Moylan, S., Jacka, F. N., Pasco, J. A., & Berk, M. (2013). How cigarette smoking may 
increase the risk of anxiety symptoms and anxiety disorders: A critical review of 
biological pathways. Brain and Behavior, 3(3), 302-326. 
Ng, J. B., Turek, M., & Hakim, A. M. (2013). Heart disease as a risk factor for dementia. 
Clinical Epidemiology, 5, 135-145.  
Nooyens, A. C. J., van Gelder, B. M., & Verschuren, W. M. M. (2008). Smoking and 
cognitive decline among middle-aged men and women: The Doetinchem Cohort 
Study. American Journal of Public Health, 98, 2244-2250. 
Ott, A., Slooter, A. J. C., Hofman, A., Van Harskamp, F., Witteman, J. C. M., Van 
Broeckhoven, . . . Breteler, M. M. B. (1998). Smoking and risk of dementia and 
Alzheimer's disease in a population-based cohort study: The Rotterdam Study. 
Lancet, 351(9119), 1840-1845. 
Ott, A., Andersen, K., Dewey, M. E., Letenneur, L., Brayne, C., Copeland, J. R. M., . . . 
Launer, L. J. (2004). Effect of smoking on global cognitive function in 
nondemented elderly. Neurology, 62, 920-924. 
Paul, R. H., Brickman, A. M., Cohen, R. A., Williams, L. M., Niaura, R. Pogun, S., . . . 
Gordon, E. (2006). Cognitive status of young and older cigarette smokers: Data 
from the international brain database. Journal of Clinical Neuroscience, 13, 457-
465. 
Peters, R. (2012). Blood pressure, smoking, and alcohol use, association with vascular 
dementia. Experimental Gerontology, 47, 865-872. 
Peters, R., Poulter, R., Warner, J., Beckett, N., Burch, L., & Bulpitt, C. (2008). Smoking, 
dementia, and cognitive decline in the elderly, a systematic review. BMC 
Geriatrics, 8, 36-42. 
Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment of 
organic brain deficit in elderly patients. Journal of the American Geriatrics 
Society, 10, 433-441. 
Pietrzack, R. H., Manruff, P., Woodward, M. Fredrickson, J., Fredrickson, A. Krystal, J. 
H., . . . Darby, D. (2012). Mild worry symptoms predict decline in learning and 
memory in healthy older adults: A 2-year prospective cohort study. American 
Journal of Geriatric Psychiatry, 20(3), 266-275. 
 46 
Powell, J. B., Cripe, L. I., & Dodrill, C. B. (1991). Assessment of brain impairment with 
the Rey Auditory-Verbal Learning Test: A comparison with other 
neuropsychological measures. Archives of Clinical Neuropsychology, 6, 241-249. 
Praticò, D. (2008). Oxidative stress hypothesis in Alzheimer’s disease: A reappraisal. 
Trends in Pharmacological Sciences, 29(12), 609-615. 
Rabinovici, G. D., & Miller, B. L. (2010). Frontotemporal lobar degeneration 
epidemiology, pathophysiology, diagnosis, and management. CNS Drugs, 24(5), 
375-398. 
Reitz, C., Luchsinger, J., Tang, M.-X., & Mayeux, R. (2005). Effect of smoking and time 
on cognitive function in the elderly without dementia. Neurology, 65, 870-875. 
Rincon, F., & Wright, C. B. (2013). Vascular cognitive impairment. Current Opinion in 
Neurology, 26, 29-36. 
Roberts, R. O., Knopman, D. S., Geda, Y. E., Cha, R. H., Pankratz, V. S., Baertlein, L., . . 
. Petersen, R. C. (2013). Association of diabetes with amnestic and nonamnestic 
mild cognitive impairment. Alzheimer’s & Dementia, 10(1), 18-26. 
Roman, G. C., & Benavente, O. (2004). The neuropathology of vascular dementia. 
Seminars in Cerebrovascular Diseases and Stroke, 4, 87-96. 
Rusanen, M., Kivipelto, M., Quesenberry Jr., C. P., Zhou, J., &Whitmer, R. A. (2011). 
Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular 
dementia. Archives of Internal Medicine, 171(4), 333-339. 
Sabia, S., Marmot, M. Dufouil, C., & Singh-Manoux, A. (2008). Smoking history and 
cognitive function in middle age from the Whitehall II Study. Archives of Internal 
Medicine, 168(11), 1165-1173. 
Sabia, S., Nabi, H., Kivimaki, M. Shipley, M. J., Marmot, M. G., & Singh-Manoux, A. 
(2009). Health behaviors form early to late midlife as predictors of cognitive 
function. American Journal of Epidemiology, 170(4), 428-437. 
Sabia, S. Elbaz, A., Dugravot, A., Head, J., Shipley, M., Hagger-Johnson, G., . . . Singh-
Manoux, A. (2012). Impact of smoking on cognitive decline in early old age: The 
Whitehall II cohort study. Archives of General Psychiatry, 69(6), 627-635. 
Scherr, P. A., Albert, M. S., Funkenstein, H. H., Cook, N. R., Hennekens, C. K., Branch, 
L. G., . . . Evans, D. A. (1988). Correlates of cognitive function in an elderly 
community population. American Journal of Epidemiology, 128(5), 1084-1101. 
Seidman, L. J., Caplan, B. B., Tolomiczenko, G. S., Turner, W. M., Penk, W. E., Schutt, 
R. K., . . . Goldfinger, S. M. (1997). Neuropsychological function in homelessness 
mentally ill individuals. Journal of Nervous and Mental Diseases, 185, 3-12. 
 47 
Shih, R. A., Glass, T. A., Bandeen-Roche, K., Carlson, M. C., Bolla, K. I., Todd, A. C., 
& Schwartz, B. S. (2006). Environmental lead exposure and cognitive function in 
community-dwelling older adults. Neurology, 67, 1556-1562. 
Sinforiani,E., Zucchella, C., Pasotti, C., Casoni, F., Bini, P., & Costa, A. (2011). The 
effects of alcohol on cognition in the elderly: From protection to 
neurodegeneration. Functional Neurology, 26(2), 103-106. 
Soubelet, A., & Salthouse, T. A. (2011). Correlates of level and change in the Mini-
Mental State Exam. Psychological Assessment, 23(4), 811-818. 
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2012). Preclinical Alzheimer disease – 
The challenge ahead. Nature Reviews Neurology, 9, 54-58. 
Starr, J. M., Deary, I. J., Fox, H. C., & Whalley, L. J. (2007). Smoking and cognitive 
change from age 11 to 66 years: A confirmatory investigation. Addictive 
Behaviors, 32, 63-68. 
Swan, G. E., & Lessov-Schlaggar, C. N. (2007). The effects of tobacco smoke and 
nicotine on cognition and the brain. Neuropsychology Review, 17, 259-273. 
Tabert, M. H., Manly, J. J., Liu, X., Pelton, G. H., Rosenblum, S., Jacobs, M., . . . 
Devanand, D. P. (2006). Neuropsychological prediction of conversion to 
Alzheimer disease in patients with mild cognitive impairment. Archives of 
General Psychiatry, 63, 916-924. 
Tsuang, D., Larson, E. B., Li, G., Shofer, J. B., Montine, K. S., Thompson, M. L., . . . 
Montine, T. J. (2009). Association between lifetime cigarette smoking and Lewy 
body accumulation. Brain Pathology, 20, 412-418. 
Tullis, L. M., Dupont, R., Frost-Pineda, K., & Gold, M. S. (2003). Marijuana and 
tobacco: A major connection. Journal of Addictive Diseases, 22(3), 51-62. 
U.S. Department of Health and Human Services. (2014). The Health Consequences of 
Smoking – 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: 
U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, National Center for Chronic Disease Prevention and Health 
Promotion, Office on Smoking and Health, 
van den Burg, W., & Kingma, A. (1999). Performance of 225 Dutch school children on 
Rey’s Auditory Verbal Learning Test (AVLT): Parallel test-retest reliabilities 
with an interval of 3 months and normative data. Archives of Clinical 
Neuropsychology, 14 (6), 545-559. 
Wang, C.-C., Lu, T.-H., Liao, W.-C., Yuan, S.-C., Kuo, P.-C., Chuang, H.-L., . . . Yen, 
C.-H. (2010). Cigarette smoking and cognitive impairment: A 10-year cohort 
study in Taiwan. Archives of Gerontology and Geriatrics, 51, 143-148. 
 48 
Weber, E., Blackstone, K., Iudicello, J. E., Morgan, E. E. Grant, I., Moore, D. J.,  . . . The 
Translational Methamphetamine AIDS Research Center (TMARC) Group. 
(2012). Neurocognitive deficits are associated with unemployment in chronic 
methamphetamine users. Drug and Alcohol Dependence, 125 (0), 146-153. 
Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007). Active 
smoking and the risk of type 2 diabetes. JAMA, 298 (22), 2654-2664. 
Zaccai, J., McCracken, C., & Brayne, C. (2005). A systematic of prevalence and 
incidence studies of dementia with Lewy bodies. Age and Ageing, 34, 561-566. 
Ziegler, J. C., Pech-Georgel, C., Dufau, S., & Grainger, J. (2010). Rapid processing of 
letters, digits, and symbols: What purely visual-attentional deficit in 
developmental dyslexia? Developmental Science, 13(4), F8-F14. 
